Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial | Zendy

John J. Bissler | Zendy; J.C. Kingswood | Zendy; Elżbieta Radzikowska | Zendy; Bernard A. Zonnenberg | Zendy; Michael Frost | Zendy; Е. Д. Белоусова | Zendy; Matthias Sauter | Zendy; Norio omura | Zendy; Susanne Brakemeier | Zendy; Petrus J. de Vries | Zendy; Noah Berkowitz | Zendy; Sara Miao | Zendy; Scott Segal | Zendy; Séverine Peyrard | Zendy; Klemens Budde | Zendy

Open Access

Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial

Author(s) -

John J. Bissler,

J.C. Kingswood,

Elżbieta Radzikowska,

Bernard A. Zonnenberg,

Michael Frost,

Е. Д. Белоусова,

Matthias Sauter,

Norio omura,

Susanne Brakemeier,

Petrus J. de Vries,

Noah Berkowitz,

Sara Miao,

Scott Segal,

Séverine Peyrard,

Klemens Budde

Publication year - 2015

Publication title -

nephrology dialysis transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.654

H-Index - 168

eISSN - 1460-2385

pISSN - 0931-0509

DOI - 10.1093/ndt/gfv249

Subject(s) - tuberous sclerosis , medicine , everolimus , tolerability , lymphangioleiomyomatosis , angiomyolipoma , clinical endpoint , adverse effect , nephrology , target lesion , placebo , randomized controlled trial , urology , surgery , gastroenterology , kidney , radiology , pathology , alternative medicine , percutaneous coronary intervention , myocardial infarction

Mammalian target of rapamycin (mTOR) inhibitors are recommended as first-line treatment of renal angiomyolipoma associated with tuberous sclerosis complex (TSC) or sporadic lymphangioleiomyomatosis (sporadic LAM), but follow-up is limited. Longer term efficacy and tolerability data from a Phase 3, double-blind, placebo-controlled trial are presented.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research